NCT03342573View on ClinicalTrials.gov

Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

April 1, 2018

Primary Completion Date

January 1, 2022

Study Completion Date

February 1, 2022

Conditions

PITYRIASIS RUBRA PILARIS

Interventions

DRUG

Cosentyx

Cosentyx 300 mg SQ week 0-4, then every q4 weeks for a total of 28 weeks.

Trial Locations (2)

32224

Mayo Clinic in Florida, Jacksonville

85259

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Mayo Clinic

OTHER